Arbor Investment Advisors’s Gyre Therapeutics GYRE Stock Holding History

Arbor Investment Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-131	Closed	-$18K	–	42
2016 Q3	$18K	Hold	131	–	–	0.01%	43
2016 Q2	$22K	Hold	131	–	–	0.01%	46
2016 Q1	$25K	Hold	131	–	–	0.02%	39
2015 Q4	$46K	Hold	131	–	–	0.03%	42
2015 Q3	$69K	Hold	131	–	–	0.04%	38
2015 Q2	$288K	Sell	131 -1	-0.8%	-$2K	0.16%	32
2015 Q1	$308K	Hold	132	–	–	0.17%	32
2014 Q4	$274K	Hold	132	–	–	0.15%	37
2014 Q3	$264K	Hold	132	–	–	0.15%	37
2014 Q2	$470K	Hold	132	–	–	0.25%	32
2014 Q1	$495K	Buy	+132	New	+$489K	0.28%	30

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Arbor Investment Advisors's GYRE Position: Q4 2016 in Review

Arbor Investment Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2016, closing a stake of 131 shares — an estimated $18K sold.

Arbor Investment Advisors first reported a position in GYRE in Q1 2014 and held it in 11 quarters. The position peaked at $495K in Q1 2014. 27 funds tracked by Wall St. Rank hold GYRE as of Q4 2016.

Arbor Investment Advisors reported no remaining Gyre Therapeutics position as of Q4 2016 after selling out during the quarter.
Arbor Investment Advisors sold 131 Gyre Therapeutics shares in Q4 2016, an estimated $18K.
Arbor Investment Advisors first reported a position in Gyre Therapeutics in Q1 2014 and held it in 11 quarters.
Arbor Investment Advisors's Gyre Therapeutics position peaked at $495K in Q1 2014.
27 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2016.

Based on Arbor Investment Advisors's 13F filing for Q4 2016, filed 13 Jan 2017.